Takeda’s Adcetris (brentuximab vedotin) has seen its marketing authorisation expanded by the European Commission to include the treatment of previously untreated CD30+ Stage IV Hodgkin lymphoma in combination with AVD (Adriamycin, vinblastine and dacarbazine) in adult patients.
Phase 3 data submitted to support the indication had demonstrated that use of the drug in combination with AVD led to a “statistically significant improvement in modified progression-free survival (PFS)” compared to ABVD (Adriamycin, bleomycin, vinblastine and dacarbazine), meeting its primary endpoint.
